Analysis of clinical effect of recombinant human granulocyte-macrophage colony-stimulating factor combined with recombinant bovine basic fibroblast growth factor in the treatment of oral ulcer caused by chemotherapy

Objective To investigate the effect of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) combined with recombinant bovine basic fibroblast growth factor (rb-bFGF) in the treatment of oral ulcer caused by chemotherapy. Methods 108 patients of oral ulcer caused by chemotherapy were randomly divided into two groups. 54 cases in the control group were treated with cydiodine buccal tablets at first, then received the aerosol treatment which was prepared by mixing gentamicin, dexamethasone, 2 % lidocaine and physiologic saline, three times per day. 54 cases in the treatment group firstly received the gargle which was prepared by mixing rhGM-CSF, dexamethasone and physiologic saline, then were treated with rb-bFGF by spraying on the oral ulcer surface, three times per day. Results The effective rate of the treatment group was 96.30 % (52/54), which was significantly higher than that of the control group [64.81 % (35/54)], there was a significant difference between the two groups (χ2=17.08, P<0.05). Conclusion The effect of rhGM-CSF combined with rb-bFGF in the treatment of oral ulcer caused by chemotherapy is very significant. Key words: Recombinant human granulocyte-macrophage colony-stimulating factor; Recombinant bovine basic fibroblast growth factor; Oral ulcer caused by chemotherapy